Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,208 | 143 | 1,050 |
| Samples | 385 | 64 | 314 |
| Peptides | 335 | 48 | 291 |
Function
NFKB1 · Nuclear factor kappa B subunit 1
This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines, oxidant-free radicals, ultraviolet irradiation, and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. NFKB is a critical regulator of the immediate-early response to viral infection. Alternative splicing results in multiple transcript variants encoding different isoforms, at least one of which is proteolytically processed. [provided by RefSeq, Aug 2020].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 316 amino-acid changes on canonical ENST00000226574 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NFKB1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NFKB1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Endometrial Carcinoma | 10/42 24% | 22/612 4% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Melanoma | 2/210 1% | 35/1899 2% |
| Colorectal Carcinoma | 15/143 10% | 44/3239 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 10/810 1% |
| Gastric Carcinoma | 3/74 4% | 18/1809 1% |
| Other Solid Cancers | 0/94 0% | 18/1515 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 8/752 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 17/1592 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 13/1390 1% |
| Other Sarcomas | 1/69 1% | 6/699 1% |
| Hepatocellular Carcinoma | 0/46 0% | 20/2210 1% |
| Cervical Carcinoma | 1/35 3% | 3/422 1% |
| Ovarian Carcinoma | 4/109 4% | 5/998 0% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Biliary Tract Carcinoma | 0/54 0% | 7/950 1% |
| Prostate Carcinoma | 0/13 0% | 13/2105 1% |
| Glioma | 0/52 0% | 12/2127 1% |
| Neuroendocrine Tumour | 2/154 1% | 2/577 0% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Head and Neck Carcinoma | 0/85 0% | 8/1574 1% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 11/2550 0% |
| Breast Carcinoma | 6/144 4% | 8/3264 0% |
| Bladder Carcinoma | 1/58 2% | 3/956 0% |
| Meningioma | 0/3 0% | 1/252 0% |
Mutation Distribution
Where NFKB1 is mutated · all tissues, split by cell line vs tissue
How many mutations in NFKB1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,208 mutations in NFKB1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|